Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

Ricardo Costa; Ami N. Shah; Cesar A. Santa-Maria; Marcelo R. Cruz; Devalingam Mahalingam; Benedito A. Carneiro; Young Kwang Chae; Massimo Cristofanilli; William J. Gradishar; Francis J. Giles

doi:10.1016/j.ctrv.2016.12.010

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

Ricardo Costa^*, Ami N. Shah, Cesar A. Santa-Maria, Marcelo R. Cruz, Devalingam Mahalingam, Benedito A. Carneiro, Young Kwang Chae, Massimo Cristofanilli, William J. Gradishar, Francis J. Giles

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

142 Scopus citations

Abstract

Triple negative breast cancer (TNBC) accounts for 10–20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.

Original language	English (US)
Pages (from-to)	111-119
Number of pages	9
Journal	Cancer Treatment Reviews
Volume	53
DOIs	https://doi.org/10.1016/j.ctrv.2016.12.010
State	Published - Feb 1 2017

Keywords

Epidermal Growth Factor Receptor
Targeted therapy
Triple negative breast cancer
mTOR

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ctrv.2016.12.010

Cite this

Costa, R., Shah, A. N., Santa-Maria, C. A., Cruz, M. R., Mahalingam, D., Carneiro, B. A., Chae, Y. K., Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017). Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer Treatment Reviews, 53, 111-119. https://doi.org/10.1016/j.ctrv.2016.12.010

@article{57440151ed4847d5af95f8d98c1c3e35,

title = "Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development",

abstract = "Triple negative breast cancer (TNBC) accounts for 10–20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.",

keywords = "Epidermal Growth Factor Receptor, Targeted therapy, Triple negative breast cancer, mTOR",

author = "Ricardo Costa and Shah, {Ami N.} and Santa-Maria, {Cesar A.} and Cruz, {Marcelo R.} and Devalingam Mahalingam and Carneiro, {Benedito A.} and Chae, {Young Kwang} and Massimo Cristofanilli and Gradishar, {William J.} and Giles, {Francis J.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = feb,

day = "1",

doi = "10.1016/j.ctrv.2016.12.010",

language = "English (US)",

volume = "53",

pages = "111--119",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Targeting Epidermal Growth Factor Receptor in triple negative breast cancer

T2 - New discoveries and practical insights for drug development

AU - Costa, Ricardo

AU - Shah, Ami N.

AU - Santa-Maria, Cesar A.

AU - Cruz, Marcelo R.

AU - Mahalingam, Devalingam

AU - Carneiro, Benedito A.

AU - Chae, Young Kwang

AU - Cristofanilli, Massimo

AU - Gradishar, William J.

AU - Giles, Francis J.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Triple negative breast cancer (TNBC) accounts for 10–20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.

AB - Triple negative breast cancer (TNBC) accounts for 10–20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.

KW - Epidermal Growth Factor Receptor

KW - Targeted therapy

KW - Triple negative breast cancer

KW - mTOR

UR - http://www.scopus.com/inward/record.url?scp=85009348128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009348128&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2016.12.010

DO - 10.1016/j.ctrv.2016.12.010

M3 - Review article

C2 - 28104566

AN - SCOPUS:85009348128

SN - 0305-7372

VL - 53

SP - 111

EP - 119

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

ER -

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this